All In Biotech

Drug Trial Radar · NCT02386800

CINC424A2X01B Rollover Protocol

Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies

Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

279

Actual

Start

Mar 5, 2015

Primary completion

Apr 5, 2032

Study completion Apr 5, 2032

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 12, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 month, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a long term safety study for patients that have been treated with either ruxolitinib or a combination of ruxolitinib with panobinostat, on a Novartis or Incyte sponsored study, who have been judged by the study Investigator to benefit from ongoing treatment.

Conditions

  • Primary Myelofibrosis
  • Polycythemia Vera
  • Graft Versus Host Disease
  • Acute Myeloid Leukemia
  • Thalassemia

Interventions

  • ruxolitinibDrug

    ruxolitinib tablets or pediatric oral solution - participants continue ruxolitinib as they received in parent study

  • panobinostatDrug

    panobinostat capsules - participants to continue receiving panobinostat in combination with ruxolitinib as per the parent study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of AEs and SAEsTime frame: 12 years

Locations

97 sites in 25 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    St Leonards, Australia

  • Novartis Investigative Site

    Darlinghurst, New South Wales, Australia

  • Novartis Investigative Site

    Herston, Queensland, Australia

  • Novartis Investigative Site

    Wooloongabba, Queensland, Australia

  • Novartis Investigative Site

    Bedford Park, South Australia, Australia

  • Novartis Investigative Site

    Box Hill, Victoria, Australia

  • Novartis Investigative Site

    Clayton, Victoria, Australia

  • Novartis Investigative Site

    Franston, Victoria, Australia

  • Novartis Investigative Site

    Perth, Western Australia, Australia

  • Novartis Investigative Site

    Antwerp, Belgium

  • Novartis Investigative Site

    Bruges, Belgium

  • Novartis Investigative Site

    Liège, Belgium

  • Novartis Investigative Site

    Leuven, Vlaams Brabant, Belgium

  • Novartis Investigative Site

    Pleven, Bulgaria

  • Novartis Investigative Site

    Plovdiv, Bulgaria

  • Novartis Investigative Site

    Sofia, Bulgaria

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Santiago, Chile

  • Novartis Investigative Site

    Santiago, RM, Chile

  • Novartis Investigative Site

    Viña del Mar, Valparaiso, Chile

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Hangzhou, Zhejiang, China

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Aachen, Germany

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Hamburg, Germany

  • Novartis Investigative Site

    Magdeburg, Germany

  • Novartis Investigative Site

    Mainz, Germany

  • Novartis Investigative Site

    Ulm, Germany

  • Novartis Investigative Site

    Dresden, Saxony, Germany

  • Novartis Investigative Site

    Jena, Thuringia, Germany

  • Novartis Investigative Site

    Athens, Greece

  • Novartis Investigative Site

    Pátrai, Greece

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Kaposvár, Hungary

  • Novartis Investigative Site

    Kecskemét, Hungary

  • Novartis Investigative Site

    Szeged, Hungary

  • Novartis Investigative Site

    Szombathely, Hungary

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, Hungary

  • Novartis Investigative Site

    Pune, Maharashtra, India

Showing 40 of 97 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.